loader
Please Wait
Applying Filters...

Seqens Seqens

X

List of All Manufacturers & Suppliers for 203389 Licensing, EU CTD Dossiers, Marketing Authorizations, Finished Dosage Formulations listed on PharmaCompass.com

Client Virtual Booth
Menu
Filters Filter
Cross PopUp
FILTER :

filter

01 CYSTEAMINE BITARTRATE (2)

filter

01 HORIZON (2)

filter

01 CAPSULE, DELAYED RELEASE;ORAL (2)

filter

01 EQ 25MG BASE (1)

02 EQ 75MG BASE (1)

filter

01 USA (2)

URL Supplier Web Content
CAPSULE, DELAYED RELEA...
EQ 25MG BASE
PROCYSBI
USA
203389
2013-04-30
RX
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
CAPSULE, DELAYED RELEA...
EQ 75MG BASE
PROCYSBI
USA
203389
2013-04-30
RX
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Looking for CTD TGA MCC DOSSIER APPLICATION 203389

Looking for CTD TGA MCC DOSSIER APPLICATION 203389 2

19

Horizon Therapeutics, based in Ireland, is a pharmaceutical company that stands out with its certifications from FDA.

One of their notable products is CYSTEAMINE BITARTRATE, with a corresponding application number 203389 and regulatory information .

proudly manufactured in the

approval since 2013-04-30

Horizon Therapeutics's PROCYSBI CAPSULE, DELAYED RELEASE;ORAL, medication with EQ 25MG BASE of CYSTEAMINE BITARTRATE.

18

Horizon Therapeutics, based in Ireland, is a pharmaceutical company that stands out with its certifications from FDA.

One of their notable products is CYSTEAMINE BITARTRATE, with a corresponding application number 203389 and regulatory information .

proudly manufactured in the

approval since 2013-04-30

Horizon Therapeutics's PROCYSBI CAPSULE, DELAYED RELEASE;ORAL, medication with EQ 75MG BASE of CYSTEAMINE BITARTRATE.

Post Enquiry
POST ENQUIRY